Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 3/20 | 0.59 |
| ▸ | HRH1 | P35367 | 3/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.59 |
| ▸ | HTR2B | P41595 | 3/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31733949 | 1.00 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL30163449 | 1.00 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL1200912 | 1.00 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL1200769 | 1.00 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL17685573 | 0.99 | SLC6A4 (0.73) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4941955 | 0.99 | SLC6A4 (0.73) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL8197696 | 0.86 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL5011928 | 0.86 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL7053900 | 0.86 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4941345 | 0.85 | SLC6A4 (0.97) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761478-B1 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-09-03 | — | — | EP | claimed |
| CN-119595799-A | Reversed-phase high performance liquid chromatography for one-test-multiple-evaluation detection of tomoxetine hydrochloride oral dissolved impurities C, D, E | 重庆希尔安药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-9604906-B2 | Process for the preparation of 3-aryloxy-3-phenylpropylamine and salt thereof | ZCL CHEMICALS LIMITED (IN) | 2017-03-28 | — | — | US | disclosed |
| US-20160107983-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-PHENYLPROPYLAMINE AND SALT THEREOF | COHANCE LIFESCIENCES LIMITED (IN) | 2016-04-21 | — | — | US | disclosed |
| EP-1761478-B1 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-09-03 | — | — | EP | disclosed |
| EP-1761478-B1 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-09-03 | — | — | EP | disclosed |
| EP-1761478-B1 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-09-03 | — | — | EP | disclosed |
| US-7378553-B2 | Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2008-05-27 | — | — | US | disclosed |
| US-7378553-B2 | Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2008-05-27 | — | — | US | disclosed |
| US-20080004470-A1 | Synthesis of Atomoxetine Hydrochloride | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| US-20080004470-A1 | Synthesis of Atomoxetine Hydrochloride | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| CN-1946678-A | Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards | TEVA PHARM FINE CHEMICALS SRL (IT) | 2007-04-11 | — | — | CN | disclosed |
| EP-1761478-A2 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-03-14 | — | — | EP | disclosed |
| EP-1761478-A2 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006004979-A3 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARM FINE CHEMICALS SRL (IT) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037055-A1 | SYNTHESIS OF ATOMOXETINE HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006004979-A2 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004979-A2 | AN ISOLATED ATOMOXETINE IMPURITY, PROCESSES FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND THEIR USE AS REFERENCE STANDARDS | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009532-A1 | Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards | TEVA PHARMCEUTICALS USA, INC. | 2006-01-12 | — | — | US | disclosed |
| EP-1346977-A1 | Method for producing aryl-aminopropanols | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004470-A1 | Synthesis of Atomoxetine Hydrochloride | SLC6A2, SLC6A4, SLC6A3 | SLC6A4 2/4885SLC6A2 1/4885CYP2D6 6/4885 |
| US-20060009532-A1 | Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards | PNMT, HTR3C, TH | SLC6A4 34/4885SLC6A2 22/4885CYP2D6 158/4885 |
| US-20160107983-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-PHENYLPROPYLAMINE AND SALT THEREOF | PAH, TYR, NAT1 | SLC6A4 162/4885SLC6A2 76/4885CYP2D6 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.